Podcasts about azd9291

  • 4PODCASTS
  • 40EPISODES
  • 11mAVG DURATION
  • ?INFREQUENT EPISODES
  • Mar 24, 2023LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about azd9291

Latest podcast episodes about azd9291

Molecule to Market: Inside the outsourcing space

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Paul Dickinson, Founder and CSO at Seda Pharmaceutical Development Services. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Paul, covering: The success factors and a behind-the-scenes look at one of AstraZeneca's fastest development programs – from the start of clinical trials to approval in just over two and a half years to meet unmet lung cancer needs How working with CROs and CDMOs led to identifying a poorly served niche between clinical development performance and rapid early-phase manufacturing Leaving AstraZeneca after years of success to bring collective expertise to a broader audience… “jumping in' and proving they had what it takes The rollercoaster of starting and growing a business, the feeling of ‘good anxiety', and why the value of a scientific mindset in running experiments has paid off in the business world Paul has held several senior science leadership roles in Academia and Large Pharma. These roles focussed on applying the best science in projects to ensure optimal product performance in the patient, thus bridging pharmaceutical and clinical disciplines. He founded Seda Pharmaceutical Development Services, a company focused on delivering pharmaceutical development (CMC) and clinical pharmacology services to the Pharma industry. Prior, Paul led AstraZeneca's clinical pharmacology program to NDA/MAA for AZD9291, which was the highest priority project in the AZ development portfolio and had been awarded ‘breakthrough therapy' status by the FDA. As a result of both his internal and external scientific leadership, he has been awarded numerous science and innovation awards by AstraZeneca. Paul has published >30 research papers, 5 patents, 2 book chapters, and presented numerous invited lectures and conference abstracts. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

GRACEcast Lung Cancer Video
Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 20, 2016 5:20


Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

west cancer institute resistance negative swedish lung acquired egfr nsclc jack west osimertinib gracecast t790m cancergrace swedish cancer institute necitumumab gcvl gcvllung rebiopsy azd9291 co1686 rociletinib
GRACEcast ALL Subjects audio and video
Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 20, 2016 5:20


Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

west cancer institute resistance negative swedish lung acquired egfr nsclc jack west osimertinib gracecast t790m cancergrace swedish cancer institute necitumumab gcvl gcvllung rebiopsy azd9291 co1686 rociletinib
GRACEcast
Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

GRACEcast

Play Episode Listen Later Apr 20, 2016 5:20


Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

west cancer institute resistance negative swedish lung acquired egfr nsclc jack west osimertinib gracecast t790m cancergrace swedish cancer institute necitumumab gcvl gcvllung rebiopsy azd9291 co1686 rociletinib
GRACEcast Lung Cancer Video
Third Generation EGFR TKIs for Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Feb 17, 2016 3:07


Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

cancer generation stage resistance iv lung mutation acquired cleveland clinic inhibitors egfr third generation nsclc pennell egfr tkis gracecast t790m cancergrace acquired resistance nathan pennell tarceva iressa gcvl gcvllung azd9291 gilotrif rociletinib merelitinib
GRACEcast
Third Generation EGFR TKIs for Acquired Resistance

GRACEcast

Play Episode Listen Later Feb 17, 2016 3:07


Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

cancer generation stage resistance iv lung mutation acquired cleveland clinic inhibitors egfr third generation nsclc pennell egfr tkis gracecast t790m cancergrace acquired resistance nathan pennell tarceva iressa gcvl gcvllung azd9291 gilotrif rociletinib merelitinib
GRACEcast ALL Subjects audio and video
Third Generation EGFR TKIs for Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Feb 17, 2016 3:07


Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

cancer generation stage resistance iv lung mutation acquired cleveland clinic inhibitors egfr third generation nsclc pennell egfr tkis gracecast t790m cancergrace acquired resistance nathan pennell tarceva iressa gcvl gcvllung azd9291 gilotrif rociletinib merelitinib
GRACEcast
Panel Q&A Session on Sequencing EGFR Treatments with Drs. Riely and West

GRACEcast

Play Episode Listen Later Jan 10, 2016 26:34


Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.

GRACEcast ALL Subjects audio and video
Panel Q&A Session on Sequencing EGFR Treatments with Drs. Riely and West

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jan 10, 2016 26:34


Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.

GRACEcast Lung Cancer Video
Panel Q&A Session on Sequencing EGFR Treatments with Drs. Riely and West

GRACEcast Lung Cancer Video

Play Episode Listen Later Jan 10, 2016 26:34


Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.

GRACEcast ALL Subjects audio and video
Treatment Options for EGFR T790M Negative Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jan 9, 2016 24:36


Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

GRACEcast Lung Cancer Video
Treatment Options for EGFR T790M Negative Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Jan 9, 2016 24:36


Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

GRACEcast
Treatment Options for EGFR T790M Negative Acquired Resistance

GRACEcast

Play Episode Listen Later Jan 9, 2016 24:36


Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

GRACEcast Lung Cancer Video
Emerging Options for T790M-Positive Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Jan 8, 2016 13:53


positive cancer patients resistance options forum memorial emerging lung mutation acquired egfr nsclc sloan kettering mskcc riely gracecast t790m cancergrace acquired resistance erlotinib tarceva nonsmall iressa afatinib gefitinib azd9291 gilotrif co1686 rociletinib
GRACEcast ALL Subjects audio and video
Emerging Options for T790M-Positive Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jan 8, 2016 13:53


positive cancer patients resistance options forum memorial emerging lung mutation acquired egfr nsclc sloan kettering mskcc riely gracecast t790m cancergrace acquired resistance erlotinib tarceva nonsmall iressa afatinib gefitinib azd9291 gilotrif co1686 rociletinib
GRACEcast
Emerging Options for T790M-Positive Acquired Resistance

GRACEcast

Play Episode Listen Later Jan 8, 2016 13:53


positive cancer patients resistance options forum memorial emerging lung mutation acquired egfr nsclc sloan kettering mskcc riely gracecast t790m cancergrace acquired resistance erlotinib tarceva nonsmall iressa afatinib gefitinib azd9291 gilotrif co1686 rociletinib
GRACEcast ALL Subjects audio and video
Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Dec 12, 2015 3:28


Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.

GRACEcast Lung Cancer Video
Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?

GRACEcast Lung Cancer Video

Play Episode Listen Later Dec 12, 2015 3:28


Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.

GRACEcast
Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?

GRACEcast

Play Episode Listen Later Dec 12, 2015 3:28


Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.

GRACEcast ALL Subjects audio and video
Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Dec 8, 2015 3:25


Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

GRACEcast Lung Cancer Video
Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

GRACEcast Lung Cancer Video

Play Episode Listen Later Dec 8, 2015 3:25


Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

GRACEcast
Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

GRACEcast

Play Episode Listen Later Dec 8, 2015 3:25


Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

GRACEcast ALL Subjects audio and video
Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Dec 7, 2015 3:28


Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.

GRACEcast Lung Cancer Video
Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?

GRACEcast Lung Cancer Video

Play Episode Listen Later Dec 7, 2015 3:28


Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.

GRACEcast
Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?

GRACEcast

Play Episode Listen Later Dec 7, 2015 3:28


Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.

GRACEcast ALL Subjects audio and video
Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Nov 20, 2015 3:24


Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

GRACEcast Lung Cancer Video
Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Nov 20, 2015 3:24


Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

GRACEcast
Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

GRACEcast

Play Episode Listen Later Nov 20, 2015 3:24


Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

GRACEcast Lung Cancer Video
Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?

GRACEcast Lung Cancer Video

Play Episode Listen Later Nov 12, 2015 5:09


Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

GRACEcast
Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?

GRACEcast

Play Episode Listen Later Nov 12, 2015 5:09


Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

GRACEcast ALL Subjects audio and video
Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Nov 12, 2015 5:09


Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

GRACEcast
The Potential Value of Repeat Biopsies in Acquired Resistance

GRACEcast

Play Episode Listen Later Oct 25, 2015 2:19


MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.

growth resistance factor memorial repeat progression isolated mutation acquired receptor biopsies egfr sloan kettering epidermal mskcc riely gracecast t790m cancergrace acquired resistance greg riely oligoprogression gcvl gcvllung azd9291 co1686 rociletinib merelitinib
GRACEcast ALL Subjects audio and video
The Potential Value of Repeat Biopsies in Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Oct 25, 2015 2:19


MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.

growth resistance factor memorial repeat progression isolated mutation acquired receptor biopsies egfr sloan kettering epidermal mskcc riely gracecast t790m cancergrace acquired resistance greg riely oligoprogression gcvl gcvllung azd9291 co1686 rociletinib merelitinib
GRACEcast Lung Cancer Video
The Potential Value of Repeat Biopsies in Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Oct 25, 2015 2:19


MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.

growth resistance factor memorial repeat progression isolated mutation acquired receptor biopsies egfr sloan kettering epidermal mskcc riely gracecast t790m cancergrace acquired resistance greg riely oligoprogression gcvl gcvllung azd9291 co1686 rociletinib merelitinib
GRACEcast Lung Cancer Video
Novel EGFR Inhibitors in the Setting of Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Nov 11, 2014 26:27


Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.

cancer institute pasi inhibitors dana farber cancer institute egfr dana farber gracecast t790m cancergrace acquired resistance erlotinib tarceva iressa afatinib dacomitinib gefitinib azd9291 gilotrif co1686 acquired resistance forum video ap26113 t790
GRACEcast
Novel EGFR Inhibitors in the Setting of Acquired Resistance

GRACEcast

Play Episode Listen Later Nov 11, 2014 26:27


Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.

cancer institute pasi inhibitors dana farber cancer institute egfr dana farber gracecast t790m cancergrace acquired resistance erlotinib tarceva iressa afatinib dacomitinib gefitinib azd9291 gilotrif co1686 acquired resistance forum video ap26113 t790
GRACEcast ALL Subjects audio and video
Novel EGFR Inhibitors in the Setting of Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Nov 11, 2014 26:27


Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.

cancer institute pasi inhibitors dana farber cancer institute egfr dana farber gracecast t790m cancergrace acquired resistance erlotinib tarceva iressa afatinib dacomitinib gefitinib azd9291 gilotrif co1686 acquired resistance forum video ap26113 t790
GRACEcast Lung Cancer Video
AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer

GRACEcast Lung Cancer Video

Play Episode Listen Later Jun 24, 2014 11:36


EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.

GRACEcast
AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer

GRACEcast

Play Episode Listen Later Jun 24, 2014 11:36


EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.

GRACEcast ALL Subjects audio and video
AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jun 24, 2014 11:36


EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.